Nexlizet: Patient Profile
*Maximally tolerated dose.
†Results based on up to a 52% LDL-C reduction with 10-mg rosuvastatin.4
‡Results based on up to a 36% LDL-C reduction with NEXLIZET.1
ASCVD=atherosclerotic cardiovascular disease; HbA1c=hemoglobin A1C; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction.
References: 1. NEXLIZET. Prescribing information. Esperion Therapeutics, Inc.; 09/2021. 2. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. 4. CRESTOR. Prescribing information. AstraZeneca; 07/2021. 5. Data on file. Protocol: ETC-1002FDC-053. August 2018.
EXPLORE THE MOA OF NEXLIZET
Interested in samples of NEXLIZET or NEXLETOL?
Find out about coverage for your eligible patients and resources for your practice
NEXLETOL and NEXLIZET are indicated as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use:The effect of NEXLETOL and NEXLIZET on cardiovascular morbidity and mortality has not been determined.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
Lactation and Pregnancy:
Please see full Prescribing Information for NEXLIZET and NEXLETOL.
Medical Information Contact Center: 1-833-377-7633 (toll free, US only), Monday-Friday, 8:00am-8:00pm ET
All trademarks and trade names are the property of their respective
© 2023 Esperion Therapeutics, Inc. All
rights reserved. 09/23 US-NXZT-2200026-3
The link you have selected will take you away from NEXLIZETHCP.com to an external website.
ESPERION Therapeutics, Inc. does not endorse and is not responsible for the content included on, or the way in which information is processed by, external websites. Linking to third-party sites is at your own risk. Your use of third-party websites is subject to the terms and conditions and the privacy policies of those individual sites.